This is an old revision of this page, as edited by Beetstra (talk | contribs) at 11:54, 31 October 2011 (Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'DrugBank').). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 11:54, 31 October 2011 by Beetstra (talk | contribs) (Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'DrugBank').)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound | |
| Clinical data | |
|---|---|
| Other names | 9-acetyl-7-(4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a691004 |
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 97% |
| Elimination half-life | 22 hours |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C26H27NO9 |
| Molar mass | 497.494 g/mol g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
Idarubicin (/ˌaɪdəˈruːbsɪn/) or 4-demethoxydaunorubicin is an anthracycline antileukemic drug. It inserts itself into DNA and prevents DNA from unwinding by interfering with the enzyme topoisomerase II. It is an analog of daunorubicin, but the absence of a methoxy group increases its fat solubility and cellular uptake.
It belongs to the family of drugs called antitumor antibiotics.
It is currently combined with cytosine arabinoside as a first line treatment of acute myeloid leukemia.
It is distributed under the trade names Zavedos (UK) and Idamycin (USA).
References
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it. |